In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on EyePoint Pharmaceuticals, with a price target of $23.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yi Chen has given his Buy rating due to a combination of factors surrounding EyePoint Pharmaceuticals’ recent developments and future prospects. The company reported a net loss higher than expected for the second quarter of 2025, but this was overshadowed by the progress in their Phase 3 trials for DURAVYU, a treatment for wet AMD. Both the LUGANO and LUCIA trials have completed enrollment with promising patient retention rates, and interim safety data aligns with previous findings, indicating a stable safety profile.
Additionally, EyePoint has initiated registration batches for DURAVYU, preparing for a potential NDA filing, and anticipates a swift U.S. launch upon approval. The estimated market value of the firm has increased, leading to a revised price target of $23 per share. The strategic advancements in their pipeline, coupled with the anticipated data from the LUGANO and LUCIA trials, underpin Yi Chen’s confidence in the company’s growth potential, justifying the Buy rating.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $25.00 price target.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EYPT in relation to earlier this year.